Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

NERVIANO, IT and BOSTON, Mass, October 2, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today it will […]
Nerviano Medical Sciences S.r.l. to present data on its ADC platform at the World ADC Summit 2023 in San Diego CA (Oct 16th-Oct 19th, 2023)

September 25th, 2023 Nerviano Medical Sciences S.r.l., a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2023 summit that will be held in San Diego (CA) from October 16th to October 19th, 2023, […]
Nerviano Medical Sciences S.r.l. partecipa alla European Biotech Week 2023 / Nerviano Medical Sciences S.r.l. participates in the European Biotech Week 2023

Nerviano Medical Sciences (NMS), una Biotech focalizzata sulla ricerca e sviluppo di farmaci Oncologici innovativi, partecipa alla Settimana Europea delle Biotecnologie (European Biotech Week – EBW), giunta quest’anno alla sua XI edizione. La EBW è una settimana di eventi e incontri in tutta Europa per raccontare le biotecnologie nei diversi settori di applicazione ad un pubblico vasto […]
Nerviano Medical Sciences S.r.l. announces preclinical data on NMS-P945, its novel proprietary payload-linker for ADC generation, published in Molecular Cancer Therapeutics

Nerviano, September 20, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A. and a clinical stage biotech, discovering and developing innovative therapies for the treatment of cancer, today announces the publication of preclinical data on NMS-P945 (link to article), its novel protease-cleavable thienoduocarmycin derivative payload-linker, with DNA damaging properties, in Molecular […]
Nerviano Medical Sciences S.r.l. names Alberto Ocana, PhD, as Global Clinical Lead

Nerviano Italy, 11 September 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that Alberto Ocana PhD, has joined the Global Clinical Development Team as Global Clinical Lead, effective immediately. In this pivotal role, […]
Nerviano Medical Sciences Announces Enhanced US Executive Team: Terrence West, MBA, Expands Role as Chief Operating Officer

NERVIANO, IT and BOSTON, Mass., August 1, 2023 – Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. […]
Nerviano Medical Sciences Announces FDA Clearance of Investigational New Drug (IND) for NMS-03592088 in positive Relapsed or Refractory Acute Myeloid Leukemia

Nerviano 22 June 2023_Nerviano Medical Sciences Srl (NMS), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, is delighted to announce the FDA Clearance of Investigational New Drug (IND) Application for NMS-03592088 (NMS-088), a novel, potent FLT3 inhibitor. NMS-088 is poised to transform the landscape of […]
Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates

NERVIANO, Italy, June 5, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS Group S.p.A. (NMS group), the largest cancer research and development company in Italy, announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) for […]
Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview

Nerviano Medical Sciences S.r.l. to Present MPSA-153-001 at ASCO 2023: Slide deck, Poster and Video Preview NMS-153: A clinical-phase, potent and highly selective small molecule inhibitor of Monopolar Spindle 1 with differentiated mechanism of action and potential for First in Class/Best in Class Nerviano, 26 May 2023 – Nerviano Medical Sciences Srl, a member […]
Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development

NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur, PhD has joined the Global Asset Leadership Team to lead the strategy and the […]